Inactive Instrument

Cerenis Therapeutics Holding Stock price Euronext Paris

Equities

FR0012616852

Biotechnology & Medical Research

Sales 2023 4.6M 4.97M Sales 2024 * 4.6M 4.97M Capitalization 29.95M 32.39M
Net income 2023 -3M -3.24M Net income 2024 * -6M -6.49M EV / Sales 2023 9.02 x
Net cash position 2023 * 100K 108K Net cash position 2024 * 3.4M 3.68M EV / Sales 2024 * 5.77 x
P/E ratio 2023 *
-6.64 x
P/E ratio 2024 *
-6.2 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 77.63%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 48 06-12-31
Director of Finance/CFO - 08-04-30
Chief Tech/Sci/R&D Officer - 15-02-08
Members of the board TitleAgeSince
Director/Board Member 54 -
Director/Board Member 75 15-02-05
Chief Executive Officer 48 06-12-31
More insiders
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2022, the company boasted a portfolio of 3 products in clinical development.
More about the company
  1. Stock
  2. Equities
  3. Stock ABIONYX Pharma
  4. Stock Cerenis Therapeutics Holding - Euronext Paris